The Asia Pacific Viral Vector Production Market would witness market growth of 20.3% CAGR during the forecast period (2023-2030).
The extensive pipeline of gene therapy and viral vaccines presents a promising outlook for the future growth of the viral vector production market. The demand for viral vectors is set to rise as they play a critical role in facilitating the delivery and efficacy of these therapies with an expanding pipeline in various therapeutic areas. The demand for viral vector production is expected to experience a substantial upsurge as more gene therapies and viral vaccines advance through clinical trials and gain regulatory approval. This favorable scenario creates an opportunity for viral vector production companies to expand their operations and cater to the increase in requirements of the dynamic biopharmaceutical industry.
The biotechnology field has undergone a revolutionary transformation recently, with viral vectors emerging as indispensable tools for gene therapy, vaccine development, and various biomedical applications. Viral vectors, primarily derived from viruses, serve as efficient vehicles for delivering therapeutic genes or genetic material into target cells. This dynamic landscape has fueled the growth of the viral vector production market, creating new opportunities and challenges for biopharmaceutical companies, research institutions, and other stakeholders.
Various governments in the Asia Pacific region are implementing initiatives to support the biopharmaceutical industry. Incentives, grants, and supportive regulatory frameworks encourage research, development, and production activities related to viral vectors. Therefore, the factors mentioned above will propel market growth in this region.
The China market dominated the Asia Pacific Viral Vector Production Market, by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $262.7 Million by 2030. The Japan market is registering a CAGR of 19.5% during (2023 - 2030). Additionally, The India market would witness a CAGR of 21.1% during (2023 - 2030).
Based on Type, the market is segmented into Adeno-Associated Viral Vectors, Lentiviral Vectors, Adenoviral Vectors, Retroviral Vectors, and Others. Based on Indication, the market is segmented into Cancer, Genetic Disorders, Infectious Diseases, and Others. Based on Application, the market is segmented into Gene Therapy, and Vaccinology. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The extensive pipeline of gene therapy and viral vaccines presents a promising outlook for the future growth of the viral vector production market. The demand for viral vectors is set to rise as they play a critical role in facilitating the delivery and efficacy of these therapies with an expanding pipeline in various therapeutic areas. The demand for viral vector production is expected to experience a substantial upsurge as more gene therapies and viral vaccines advance through clinical trials and gain regulatory approval. This favorable scenario creates an opportunity for viral vector production companies to expand their operations and cater to the increase in requirements of the dynamic biopharmaceutical industry.
The biotechnology field has undergone a revolutionary transformation recently, with viral vectors emerging as indispensable tools for gene therapy, vaccine development, and various biomedical applications. Viral vectors, primarily derived from viruses, serve as efficient vehicles for delivering therapeutic genes or genetic material into target cells. This dynamic landscape has fueled the growth of the viral vector production market, creating new opportunities and challenges for biopharmaceutical companies, research institutions, and other stakeholders.
Various governments in the Asia Pacific region are implementing initiatives to support the biopharmaceutical industry. Incentives, grants, and supportive regulatory frameworks encourage research, development, and production activities related to viral vectors. Therefore, the factors mentioned above will propel market growth in this region.
The China market dominated the Asia Pacific Viral Vector Production Market, by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $262.7 Million by 2030. The Japan market is registering a CAGR of 19.5% during (2023 - 2030). Additionally, The India market would witness a CAGR of 21.1% during (2023 - 2030).
Based on Type, the market is segmented into Adeno-Associated Viral Vectors, Lentiviral Vectors, Adenoviral Vectors, Retroviral Vectors, and Others. Based on Indication, the market is segmented into Cancer, Genetic Disorders, Infectious Diseases, and Others. Based on Application, the market is segmented into Gene Therapy, and Vaccinology. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
List of Key Companies Profiled
- Andelyn Biosciences, Inc.
- Charles River Laboratories International, Inc.
- Danaher Corporation
- FinVector Oy (Ferring Ventures S/A)
- Thermo Fisher Scientific, Inc.
- Novartis AG
- Takara Bio Inc. (Takara Holdings Inc.)
- Avid Bioservices, Inc.
- Oxford Biomedica plc
- Lonza Group Ltd.
Market Report Segmentation
By Type- Adeno-Associated Viral Vectors
- Lentiviral Vectors
- Adenoviral Vectors
- Retroviral Vectors
- Others
- Cancer
- Genetic Disorders
- Infectious Diseases
- Others
- Gene Therapy
- Vaccinology
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 5. Asia Pacific Viral Vector Production Market, by Type
Chapter 6. Asia Pacific Viral Vector Production Market, by Indication
Chapter 7. Asia Pacific Viral Vector Production Market, by Application
Chapter 8. Asia Pacific Viral Vector Production Market, by Country
Chapter 9. Company Profiles
Companies Mentioned
- Andelyn Biosciences, Inc.
- Charles River Laboratories International, Inc.
- Danaher Corporation
- FinVector Oy (Ferring Ventures S/A)
- Thermo Fisher Scientific, Inc.
- Novartis AG
- Takara Bio Inc. (Takara Holdings Inc.)
- Avid Bioservices, Inc.
- Oxford Biomedica plc
- Lonza Group Ltd.
Methodology
LOADING...
